Kymera Therapeutics is a clinical-stage biopharmaceutical company that is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. The company's proprietary targeted protein degradation platform, Pegasus, is designed to harness the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on undruggable and difficult-to-drug targets. Kymera's initial programs are focused on oncology and immunology, with a goal of delivering transformative therapies for patients with previously untreatable diseases. Kymera was founded in 2015 and is headquartered in Cambridge, MA.